Baltimores KaloCyte Partners on 46M DARPA Program to Develop Synthetic Blood Product BioBuzzKaloCyte’s experimental synthetic red blood cell product ErythroMer could provide a solution to the high need for treating trauma in both military and civilian settings. The company was tapped to participate in a federally-funded program to develop a synthetic blood substitute.

Image: https://biobuzz.io/